Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)
Clinical trial NCT00002079 · COMPLETED
Trial details
- NCT number
- NCT00002079
- Sponsor
- G D Searle
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.